Brown R O, Hamrick K D, Dickerson R N, Lee N, Parnell D H, Kudsk K A
Department of Clinical Pharmacy, University of Tennessee, Memphis 38163, USA.
JPEN J Parenter Enteral Nutr. 1996 Nov-Dec;20(6):429-32. doi: 10.1177/0148607196020006429.
We report a case of probable combined octreotide- and heparin-induced hyperkalemia. The patient had been receiving home parenteral nutrition, enoxaparin, and octreotide for 10 months. She required very little potassium in her PN solution to maintain serum potassium concentrations in the normal range. The patient reportedly did not receive other medications or have clinical conditions that, to our knowledge, cause hyperkalemia. She maintained normal renal function throughout the hospitalization and did not appear to have any significant acid-base disorders. Practitioners should be aware of the potential for octreotide and heparin to cause hyperkalemia. Regular monitoring of serum potassium concentrations should be done for patients receiving octreotide and heparin to avoid hyperkalemia.
我们报告一例可能由奥曲肽和肝素联合导致的高钾血症病例。该患者接受家庭肠外营养、依诺肝素和奥曲肽治疗已达10个月。她在肠外营养溶液中所需的钾极少,就能将血清钾浓度维持在正常范围内。据报道,该患者未服用其他药物,据我们所知也没有可导致高钾血症的临床病症。在整个住院期间,她的肾功能保持正常,且似乎没有任何明显的酸碱平衡紊乱。医生应意识到奥曲肽和肝素导致高钾血症的可能性。对于接受奥曲肽和肝素治疗的患者,应定期监测血清钾浓度,以避免发生高钾血症。